Metastatic melanoma and matrix metalloproteinases

Gregory Riedlinger; Stephen Kridel; Ali M. Al-Housseini; Jennifer M. Brow; Thomas H. Bugge; Stephen H. Leppla; Nick Duesbery; George Vande Woude; Arthur Frankel

doi:10.1358/dof.2003.028.09.857377

Metastatic melanoma and matrix metalloproteinases

Gregory Riedlinger, Stephen Kridel, Ali M. Al-Housseini, Jennifer M. Brow, Thomas H. Bugge, Stephen H. Leppla, Nick Duesbery, George Vande Woude, Arthur Frankel

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Metastatic melanoma is a rapidly progressive, incurable malignancy for which novel therapies are needed. Analysis of the biology of melanoma cells reveals a dependency upon several critical pathways, with matrix metalloproteinases (MMPs) essential for tumor spread and dissemination. We describe a growing number of protein therapeutics which target melanoma cells by requiring activation by MMPs. These agents should have distinct side effects and may be useful in combinations with standard-cytotoxic chemotherapy or immunotherapies.

Original language	English (US)
Pages (from-to)	897-904
Number of pages	8
Journal	Drugs of the Future
Volume	28
Issue number	9
DOIs	https://doi.org/10.1358/dof.2003.028.09.857377
State	Published - Sep 2003
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2003.028.09.857377

Cite this

@article{f35efdc8814443a18939a980647f3671,

title = "Metastatic melanoma and matrix metalloproteinases",

abstract = "Metastatic melanoma is a rapidly progressive, incurable malignancy for which novel therapies are needed. Analysis of the biology of melanoma cells reveals a dependency upon several critical pathways, with matrix metalloproteinases (MMPs) essential for tumor spread and dissemination. We describe a growing number of protein therapeutics which target melanoma cells by requiring activation by MMPs. These agents should have distinct side effects and may be useful in combinations with standard-cytotoxic chemotherapy or immunotherapies.",

author = "Gregory Riedlinger and Stephen Kridel and Al-Housseini, {Ali M.} and Brow, {Jennifer M.} and Bugge, {Thomas H.} and Leppla, {Stephen H.} and Nick Duesbery and {Vande Woude}, George and Arthur Frankel",

year = "2003",

month = sep,

doi = "10.1358/dof.2003.028.09.857377",

language = "English (US)",

volume = "28",

pages = "897--904",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Clarivate",

number = "9",

}

TY - JOUR

T1 - Metastatic melanoma and matrix metalloproteinases

AU - Riedlinger, Gregory

AU - Kridel, Stephen

AU - Al-Housseini, Ali M.

AU - Brow, Jennifer M.

AU - Bugge, Thomas H.

AU - Leppla, Stephen H.

AU - Duesbery, Nick

AU - Vande Woude, George

AU - Frankel, Arthur

PY - 2003/9

Y1 - 2003/9

N2 - Metastatic melanoma is a rapidly progressive, incurable malignancy for which novel therapies are needed. Analysis of the biology of melanoma cells reveals a dependency upon several critical pathways, with matrix metalloproteinases (MMPs) essential for tumor spread and dissemination. We describe a growing number of protein therapeutics which target melanoma cells by requiring activation by MMPs. These agents should have distinct side effects and may be useful in combinations with standard-cytotoxic chemotherapy or immunotherapies.

AB - Metastatic melanoma is a rapidly progressive, incurable malignancy for which novel therapies are needed. Analysis of the biology of melanoma cells reveals a dependency upon several critical pathways, with matrix metalloproteinases (MMPs) essential for tumor spread and dissemination. We describe a growing number of protein therapeutics which target melanoma cells by requiring activation by MMPs. These agents should have distinct side effects and may be useful in combinations with standard-cytotoxic chemotherapy or immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=0345732697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345732697&partnerID=8YFLogxK

U2 - 10.1358/dof.2003.028.09.857377

DO - 10.1358/dof.2003.028.09.857377

M3 - Review article

AN - SCOPUS:0345732697

SN - 0377-8282

VL - 28

SP - 897

EP - 904

JO - Drugs of the Future

JF - Drugs of the Future

IS - 9

ER -

Metastatic melanoma and matrix metalloproteinases

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this